Zimmerman and colleagues examined how many depressed patients who scored in the remission range on the 17-item Hamilton Depression Rating Scale (HDRS) did not consider themselves to be in remission ...
Adding lumateperone (Caplyta; Johnson & Johnson) to ongoing antidepressant therapy (ADT) significantly improved depression severity in adults with major depressive disorder (MDD) who had not responded ...
Additional widely validated and reliable screening instruments are available as initial depression screening tools. The Hamilton Depression Rating Scale (HAM-D or HDRS) is a clinician-administered ...
The MarketWatch News Department was not involved in the creation of this content. -- Achieved Primary Endpoint with 30mg Dose of RE104 Demonstrating 23.0-Point Reduction from Baseline in ...
In a small study of adults with major depression, Johns Hopkins Medicine researchers report that two doses of the psychedelic substance psilocybin, given with supportive psychotherapy, produced rapid ...
Caplyta (lumateperone) was approved for the treatment of schizophrenia in 2019 and for depressive episodes linked to bipolar I or bipolar II disorder (bipolar depression) in 2021. Caplyta can be used ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback